Home › Lung Cancer › North Carolina
Lung Cancer clinical trials in North Carolina
50 studies for Lung Cancer are looking for participants at sites in North Carolina.
Cities in North Carolina
- Durham33 studies
- Charlotte9 studies
- Winston-Salem8 studies
- Wilson4 studies
- Asheville4 studies
- Raleigh4 studies
- Greensboro3 studies
- Goldsboro3 studies
- Jacksonville3 studies
- Concord3 studies
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Messino Cancer Centers Asheville, Asheville
- Duke University Medical Center Duke Cancer Center, Durham
- FirstHealth Cancer Center, Pinehurst
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Nov 13, 2026 · NCT05920356A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Local Institution - 0514, Winston-Salem
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07063745This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Brody School of Medicine at East Carolina University, Greenville
- ECU Health Medical Center, Greenville
- Carolina Cancer Research Center, Wilson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06758401Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- Wake Forest University at Clemmons, Clemmons
- and 9 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04267848Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Southeastern Medical Oncology Center-Clinton, Clinton
- Durham VA Medical Center, Durham
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- and 1 more
RecruitingPhase 3
Ages 70 and older · All sexes · Updated Nov 12, 2026 · NCT06096844A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients
- Atrium Health Wake Forest Baptist, Winston-Salem
Recruiting
Ages 50 to 77 · All sexes · Updated Nov 10, 2026 · NCT07322367A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- GSK Investigational Site, Wilson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07099898The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Nov 6, 2026 · NCT06995898A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Firsthealth of The Carolinas, Pinehurst
- WakeMed, Raleigh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06793215Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- and 6 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Novant Health Presbyterian Medical Center, Charlotte
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- and 6 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT04181060A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0100, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07492680Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
Recruiting
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07059884A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- University of North Carolina Medical Center, Chapel Hill
- Duke Cancer Institute, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06119581Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Fletcher Hospital, Inc. dba AdventHealth Hendersonville, Hendersonville
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT06712316Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Cabarrus/LCI-Concord, Concord
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06287775Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- FirstHealth Cancer Center, Pinehurst
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT05168566A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06835569Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- Durham VA Medical Center, Durham, NC, Durham
Recruiting
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT02984761Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- University of North Carolina at Chapel Hill, Chapel Hill
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT06922591UNC Pleural Fluid Registry
- UNC Lingeberger Comprehensive Cancer Center, Chapel Hill
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT05620329Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Duke University School of Medicine, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT05786924A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Charlotte
- Durham Veterans Affairs Health Care System, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07128199Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
RecruitingPhase 2
18 Minutes · All sexes · Updated Oct 9, 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Durham VA Medical Center, Durham
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06616584Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- FirstHealth Cancer Center, Pinehurst
- FirstHealth Moore Regional Hospital, Pinehurst
- Carolina Cancer Research Center, Wilson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07222566The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Carolinas Medical Center, Charlotte
- Duke Cancer Center, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06765109A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07127874A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
- GSK Investigational Site, Wilson
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07602855Study of Trilaciclib and Lurbinectidin
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05578326Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07685938Effects of Infusion Timing on Treatment Response in Solid Tumors
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07630168Health Education Approach to Lung Screening
- University of North Carolina-Chapel Hill, Carrboro
RecruitingHealthy volunteers welcome
Ages 50 to 80 · All sexes · Updated Aug 25, 2026 · NCT06070870Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Duke Cancer Center Cary, Cary
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- and 35 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05624996Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Charlotte
- Xencor Investigative Site, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05433142A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- University of North Carolina at Chapel Hill, Chapel Hill
- Duke University Medical Center, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05652686PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
Recruiting
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT06896162Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
- Levine Cancer Institute, Charlotte
RecruitingHealthy volunteers welcome
Ages 40 to 54 · All sexes · Updated Jul 13, 2026 · NCT04577599From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.